Cytokine Profiling of Systemic Sclerosis–Related Pulmonary Hypertension
Arthritis & Rheumatology · 24.05.2026
DOI: 10.1002/art.70222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 24.05.2026. Verfasst von Justin K Lui und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Pulmonary Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts. Die Arbeit nennt 15 Literaturangaben. Gefördert von: American Heart Association, Bristol-Myers Squibb, NCATS NIH HHS.
Abstract (Originalsprache)
Objective
The study objective was to use multiplex immunoassays to create a cytokine profile specific for systemic sclerosis–related pulmonary hypertension (SSc‐PH) by assessing circulating plasma of patients with SSc.
Methods
This was an observational single‐center study using plasma samples collected from 106 patients with SSc (24 with SSc‐PH by right heart catheterization) in which we measured 48 circulating cytokines using multiplex immunoassays. We applied a random forest approach to create a full 48‐cytokine model and a subsequent collapsed model based on variable importance by the mean decrease in the Gini index. The model was internally validated using a train‐test split of the data from which we generated receiver operating characteristic curves and calculated sensitivity, specificity, and accuracy.
Results
The 48‐cytokine model achieved an area under the curve of 0.82 (95% confidence interval [CI] 0.62–1.00). Monokine induced by gamma interferon was the most important cytokine associated with SSc‐PH by Gini index. Using the elbow method, a collapsed model was achieved using six cytokines (monokine induced by gamma interferon, interleukin‐8, macrophage inflammatory protein‐1β, interleukin‐15, interleukin‐7, and macrophage‐derived chemokine) that yielded an area under the curve of 0.83 (95% CI 0.72–1.00) with a sensitivity, specificity, and accuracy of 0.14 (95% CI 0.00–0.58), 0.96 (95% CI 0.80–1.00), and 0.78 (95% CI 0.60–0.91), respectively.
Conclusion
Using a single‐center SSc cohort that reflects real‐world heterogeneity, we generated a highly specific cytokine profile for SSc‐PH through a random forest approach. Future work will need to externally validate the cytokine profile through prospective cohorts.
Autor:innen und Institutionen
- The Pulmonary Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.
- Section of Rheumatology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.
- Department of Medicine, MetroWest Medical Center, Framingham, Massachusetts.
- Analytical Instrumentation Core, Boston University Medical Campus, Boston, Massachusetts.
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
- Section of Cardiovascular Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.
ORCID-Profile: Justin K Lui, Andreea M Bujor
Förderung
- American Heart Association
- Bristol-Myers Squibb
- NCATS NIH HHS
- HRSA HHS
- Novo Nordisk
- Novartis
- National Scleroderma Foundation
- School of Medicine, Boston University
Zitieren
APA
Lui, J. K., Patel, R., Luong, H. L., Au, M., El-Adili, F., Chamis, B., Trojanowski, M. A., LaValley, M. P., Gopal, D. M., Klings, E. S., & Bujor, A. M. (2026). Cytokine Profiling of Systemic Sclerosis–Related Pulmonary Hypertension. Arthritis & Rheumatology. https://doi.org/10.1002/art.70222
Vancouver
Lui JK, Patel R, Luong HL, Au M, El-Adili F, Chamis B, et al. Cytokine Profiling of Systemic Sclerosis–Related Pulmonary Hypertension. Arthritis & Rheumatology. 2026. doi:10.1002/art.70222
BibTeX
@article{Lui2026,
author = {Lui, Justin K and Patel, Rutvi and Luong, Haile L and Au, Matthew and El-Adili, Fatima and Chamis, Benjamin and Trojanowski, Marcin A and LaValley, Michael P and Gopal, Deepa M and Klings, Elizabeth S and Bujor, Andreea M},
title = {Cytokine Profiling of Systemic Sclerosis–Related Pulmonary Hypertension},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70222}
}
EUVIMED